Celestica Inc. (CLS) At $10.25 Forms Bottom; Profile of 7 Analysts Covering Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NYSE:NVO) Logo

Among 15 analysts covering Novo Nordisk (ADR) (NYSE:NVO), 7 have Buy rating, 0 Sell and 8 Hold. Therefore 47% are positive. Novo Nordisk (ADR) had 21 analyst reports since August 28, 2015 according to SRatingsIntel. The stock has “Buy” rating by Bank of America on Wednesday, December 6. JP Morgan downgraded Novo Nordisk A/S (NYSE:NVO) on Friday, September 9 to “Neutral” rating. DNB Markets downgraded the stock to “Hold” rating in Monday, October 31 report. Leerink Swann initiated the stock with “Market Perform” rating in Friday, August 28 report. The stock of Novo Nordisk A/S (NYSE:NVO) earned “Hold” rating by J.P. Morgan on Friday, December 29. Bank of America downgraded the shares of NVO in report on Friday, October 28 to “Underperform” rating. The stock of Novo Nordisk A/S (NYSE:NVO) has “Strong Buy” rating given on Monday, October 19 by Jyske Bank. Piper Jaffray initiated the stock with “Neutral” rating in Friday, September 23 report. Morgan Stanley downgraded the shares of NVO in report on Thursday, September 1 to “Equal-Weight” rating. The firm has “Overweight” rating by Morgan Stanley given on Friday, December 1. See Novo Nordisk A/S (NYSE:NVO) latest ratings:

19/01/2018 Broker: Goldman Sachs Rating: Buy Maintain
08/01/2018 Broker: Deutsche Bank Rating: Buy
29/12/2017 Broker: J.P. Morgan Rating: Hold Upgrade
29/12/2017 Broker: JP Morgan Old Rating: Underweight New Rating: Neutral Upgrade
06/12/2017 Broker: Bank of America Rating: Buy Upgrade
01/12/2017 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Upgrade

Celestica Inc. (CLS) formed multiple bottom with $9.94 target or 3.00% below today’s $10.25 share price. Celestica Inc. (CLS) has $1.42B valuation. The stock decreased 0.49% or $0.05 during the last trading session, reaching $10.25. About 56,556 shares traded. Celestica Inc. (NYSE:CLS) has declined 26.94% since April 13, 2017 and is downtrending. It has underperformed by 38.49% the S&P500.

Analysts await Celestica Inc. (NYSE:CLS) to report earnings on April, 19. They expect $0.16 earnings per share, down 33.33% or $0.08 from last year’s $0.24 per share. CLS’s profit will be $22.13 million for 16.02 P/E if the $0.16 EPS becomes a reality. After $0.10 actual earnings per share reported by Celestica Inc. for the previous quarter, Wall Street now forecasts 60.00% EPS growth.

Among 12 analysts covering Celestica (NYSE:CLS), 3 have Buy rating, 0 Sell and 9 Hold. Therefore 25% are positive. Celestica has $15.5000 highest and $0.75 lowest target. $12.80’s average target is 24.88% above currents $10.25 stock price. Celestica had 36 analyst reports since October 21, 2015 according to SRatingsIntel. The company was maintained on Monday, January 18 by RBC Capital Markets. Citigroup upgraded it to “Neutral” rating and $15 target in Friday, April 7 report. The stock has “Hold” rating by Stifel Nicolaus on Wednesday, January 24. The stock of Celestica Inc. (NYSE:CLS) earned “Hold” rating by BMO Capital Markets on Wednesday, January 24. The rating was maintained by RBC Capital Markets on Monday, May 29 with “Hold”. The stock has “Hold” rating by Macquarie Research on Thursday, June 22. As per Friday, October 30, the company rating was downgraded by RBC Capital Markets. RBC Capital Markets maintained it with “Sector Perform” rating and $14.0 target in Wednesday, October 21 report. Macquarie Research downgraded Celestica Inc. (NYSE:CLS) on Friday, July 29 to “Neutral” rating. RBC Capital Markets maintained it with “Hold” rating and $13.0 target in Friday, October 27 report.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. The company has market cap of $118.24 billion. It operates in two divisions, Diabetes and Obesity Care, and Biopharmaceuticals. It has a 19.42 P/E ratio. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, and oral anti-diabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles.

Celestica Inc. (NYSE:CLS) Ratings Chart